Loading...
TAUNS Laboratories, Inc.
197A.T•JPX
Healthcare
Medical - Specialties
¥538.00
¥-10.00(-1.82%)
TAUNS Laboratories, Inc. (197A.T) Financial Performance & Statements
Review TAUNS Laboratories, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
17.62%
↑ 17.62%
Operating Income Growth
61.66%
↑ 61.66%
Net Income Growth
90.26%
↑ 90.26%
Operating Cash Flow Growth
414.64%
↑ 414.64%
Operating Margin
46.44%
↑ 46.44%
Gross Margin
70.53%
↑ 70.53%
Net Profit Margin
33.11%
↑ 33.11%
ROE
42.10%
↑ 42.10%
ROIC
34.10%
↑ 34.10%
TAUNS Laboratories, Inc. (197A.T) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for TAUNS Laboratories, Inc. stock.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|
| Revenue | $5.56B | $6.42B | $2.06B |
| Cost of Revenue | $1.65B | $1.61B | $875.17M |
| Gross Profit | $3.91B | $4.81B | $1.19B |
| Gross Profit Ratio | $0.70 | $0.75 | $0.58 |
| R&D Expenses | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $1.12B | $1.07B | $1.08B |
| Operating Expenses | $1.12B | $1.07B | $1.38B |
| Total Costs & Expenses | -$2.77B | -$2.67B | $2.26B |
| Interest Income | $579000.00 | $1.40M | $572000.00 |
| Interest Expense | $17.74M | $15.78M | $12.77M |
| Depreciation & Amortization | $178.13M | $171.97M | $169.48M |
| EBITDA | $2.97B | $3.94B | -$124.82M |
| EBITDA Ratio | $0.53 | $0.61 | -$0.06 |
| Operating Income | $2.79B | $3.75B | -$195.99M |
| Operating Income Ratio | $0.50 | $0.58 | -$0.09 |
| Other Income/Expenses (Net) | -$21.97M | $10.09M | -$215.46M |
| Income Before Tax | $2.77B | $3.76B | -$411.45M |
| Income Before Tax Ratio | $0.50 | $0.58 | -$0.20 |
| Income Tax Expense | $781.12M | $1.06B | -$279.002M |
| Net Income | $1.99B | $2.70B | -$132.45M |
| Net Income Ratio | $0.36 | $0.42 | -$0.06 |
| EPS | $19.57 | $26.82 | -$1.32 |
| Diluted EPS | $18.55 | $25.20 | -$1.32 |
| Weighted Avg Shares Outstanding | $101.69M | $100.53M | $100.00M |
| Weighted Avg Shares Outstanding (Diluted) | $107.27M | $107.01M | $100.00M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan